178 related articles for article (PubMed ID: 38003255)
21. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins.
Naeimi Kararoudi M; Dolatshad H; Trikha P; Hussain SA; Elmas E; Foltz JA; Moseman JE; Thakkar A; Nakkula RJ; Lamb M; Chakravarti N; McLaughlin KJ; Lee DA
J Vis Exp; 2018 Jun; (136):. PubMed ID: 29985369
[TBL] [Abstract][Full Text] [Related]
22. HLA Class I Knockout Converts Allogeneic Primary NK Cells Into Suitable Effectors for "Off-the-Shelf" Immunotherapy.
Hoerster K; Uhrberg M; Wiek C; Horn PA; Hanenberg H; Heinrichs S
Front Immunol; 2020; 11():586168. PubMed ID: 33584651
[TBL] [Abstract][Full Text] [Related]
23. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
Front Immunol; 2018; 9():3152. PubMed ID: 30705677
[TBL] [Abstract][Full Text] [Related]
24. Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self.
Michen S; Frosch J; Füssel M; Schackert G; Momburg F; Temme A
Cytotherapy; 2020 Jul; 22(7):354-368. PubMed ID: 32451262
[TBL] [Abstract][Full Text] [Related]
25. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
26. Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML.
Brauneck F; Seubert E; Wellbrock J; Schulze Zur Wiesch J; Duan Y; Magnus T; Bokemeyer C; Koch-Nolte F; Menzel S; Fiedler W
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884723
[TBL] [Abstract][Full Text] [Related]
27. Genetical engineering for NK and T cell immunotherapy with CRISPR/Cas9 technology: Implications and challenges.
Zhi L; Su X; Yin M; Zhang Z; Lu H; Niu Z; Guo C; Zhu W; Zhang X
Cell Immunol; 2021 Nov; 369():104436. PubMed ID: 34500148
[TBL] [Abstract][Full Text] [Related]
28. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors.
Della Chiesa M; Vitale M; Carlomagno S; Ferlazzo G; Moretta L; Moretta A
Eur J Immunol; 2003 Jun; 33(6):1657-66. PubMed ID: 12778484
[TBL] [Abstract][Full Text] [Related]
29. Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy.
Blake SJ; Dougall WC; Miles JJ; Teng MW; Smyth MJ
Clin Cancer Res; 2016 Nov; 22(21):5183-5188. PubMed ID: 27620276
[TBL] [Abstract][Full Text] [Related]
30. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
[TBL] [Abstract][Full Text] [Related]
31. Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion.
Freeman AJ; Vervoort SJ; Ramsbottom KM; Kelly MJ; Michie J; Pijpers L; Johnstone RW; Kearney CJ; Oliaro J
Cell Rep; 2019 Sep; 28(11):2784-2794.e5. PubMed ID: 31509742
[TBL] [Abstract][Full Text] [Related]
32. NK Cell Dysfunction and Checkpoint Immunotherapy.
Bi J; Tian Z
Front Immunol; 2019; 10():1999. PubMed ID: 31552017
[TBL] [Abstract][Full Text] [Related]
33. A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy.
Pomeroy EJ; Hunzeker JT; Kluesner MG; Lahr WS; Smeester BA; Crosby MR; Lonetree CL; Yamamoto K; Bendzick L; Miller JS; Geller MA; Walcheck B; Felices M; Webber BR; Starr TK; Moriarity BS
Mol Ther; 2020 Jan; 28(1):52-63. PubMed ID: 31704085
[TBL] [Abstract][Full Text] [Related]
34. Interaction between nectin-1 and the human natural killer cell receptor CD96.
Holmes VM; Maluquer de Motes C; Richards PT; Roldan J; Bhargava AK; Orange JS; Krummenacher C
PLoS One; 2019; 14(2):e0212443. PubMed ID: 30759143
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia.
Sandoval-Borrego D; Moreno-Lafont MC; Vazquez-Sanchez EA; Gutierrez-Hoya A; López-Santiago R; Montiel-Cervantes LA; Ramírez-Saldaña M; Vela-Ojeda J
Arch Med Res; 2016 Jan; 47(1):55-64. PubMed ID: 26876298
[TBL] [Abstract][Full Text] [Related]
36. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications.
Sivori S; Vacca P; Del Zotto G; Munari E; Mingari MC; Moretta L
Cell Mol Immunol; 2019 May; 16(5):430-441. PubMed ID: 30778167
[TBL] [Abstract][Full Text] [Related]
37. Rapid and efficient generation of antigen-specific isogenic T cells from cryopreserved blood samples.
Eerkens AL; Vledder A; van Rooij N; Foijer F; Nijman HW; de Bruyn M
Immunol Cell Biol; 2022 Apr; 100(4):285-295. PubMed ID: 35194830
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles.
Jo DH; Kaczmarek S; Shin O; Wang L; Cowan J; McComb S; Lee SH
Mol Ther Methods Clin Dev; 2023 Jun; 29():173-184. PubMed ID: 37063482
[TBL] [Abstract][Full Text] [Related]
39. Permanent silencing of NKG2A expression for cell-based therapeutics.
Figueiredo C; Seltsam A; Blasczyk R
J Mol Med (Berl); 2009 Feb; 87(2):199-210. PubMed ID: 19002424
[TBL] [Abstract][Full Text] [Related]
40. Drug target validation in primary human natural killer cells using CRISPR RNP.
Rautela J; Surgenor E; Huntington ND
J Leukoc Biol; 2020 Oct; 108(4):1397-1408. PubMed ID: 33463756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
